Narsoplimab

Narsoplimab (OMS 721) is a high-affinity fully human immunoglobulin gamma 4 (IgG4) monoclonal antibody that binds MASP-2 and blocks lectin pathway activation. Narsoplimab can be used in research of hematopoietic stem-cell transplantation and SARS-CoV-2[1].

Research Areas >> Infection

Signaling Pathways >> Anti-infection >> SARS-CoV

Narsoplimab (100 nM; 3 h; Vero E6 细胞和带有 SARS-CoV-2 的 Vero E6 细胞) 抑制了 N 蛋白增强的 MASP-2 沉积[1]。

Narsoplimab (10 mg/kg; i.v.; WT and Masp2-/- (KO) mice) 降低了小鼠淋巴细胞百分比 (Lym%)，增加了中性粒细胞百分比 (Neu%)[1]。 Animal Model: WT and Masp2-/- (KO) mice (C57BL/6N, female, 12-15 weeks old)[1] Dosage: 10 mg/kg Administration: Intravenous injection Result: Decreased percentage of lymphocytes (Lym%) and an increased percentage of neutrophils (Neu%).

[1]. Gao T, et, al. Highly pathogenic coronavirus N protein aggravates inflammation by MASP-2-mediated lectin complement pathway overactivation. Signal Transduct Target Ther. 2022 Sep 14;7(1):318.